Quick Answer
Ergothioneine Blood Pressure Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Aim To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community-dwelling older population.
Key Takeaways
- 01Aim To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community-dwelling older population. [Meng X (2025)]
- 02Cox proportional hazards models were used to estimate the hazard ratios (HRs) and their 95% confidence intervals for the association between serum ergothioneine levels and the risk of dementia subtypes. [Meng X (2025)]
- 03The age- and sex-adjusted HRs for all-cause dementia, AD, and non-AD dementia decreased progressively across increasing quartiles of serum ergothioneine (all P for trend Conclusions Our findings showed that higher serum ergothioneine levels were associated with a lower risk of developing all-cause dementia, AD, and non-AD dementia in an older Japanese population. [Meng X (2025)]
- 04Methods In this prospective longitudinal analysis of participants enrolled in the Hisayama Study, 1344 Japanese community-residents aged 65 years and over without dementia at baseline were followed prospectively for a median of 11.2 years (2012-2023). [Meng X (2025)]
The current Migaku evidence database contains 2 reusable source documents for Ergothioneine Blood Pressure Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Aim To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community-dwelling older population. [Meng X (2025); evidence level 4]
- Cox proportional hazards models were used to estimate the hazard ratios (HRs) and their 95% confidence intervals for the association between serum ergothioneine levels and the risk of dementia subtypes. [Meng X (2025); evidence level 4]
- The age- and sex-adjusted HRs for all-cause dementia, AD, and non-AD dementia decreased progressively across increasing quartiles of serum ergothioneine (all P for trend Conclusions Our findings showed that higher serum ergothioneine levels were associated with a lower risk of developing all-cause dementia, AD, and non-AD dementia in an older Japanese population. [Meng X (2025); evidence level 4]
- Methods In this prospective longitudinal analysis of participants enrolled in the Hisayama Study, 1344 Japanese community-residents aged 65 years and over without dementia at baseline were followed prospectively for a median of 11.2 years (2012-2023). [Meng X (2025); evidence level 4]
- This is particularly important for at-risk populations such as Apolipoprotein E () ε4 allele carriers (), those with a family history of dementia (), and those at an early stage of cognitive decline, known as Subjective Cognitive Decline (SCD) (). [Shan Jiatong (2025); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources